Drug name - Bendeka

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

availability in other generic markets.

Click on the highlighted region to filter.